Evidence map›Paper›PMID 39264172›Full record

ArticlemBio2024

Antibody sequence determinants of viral antigen specificity.

Alexandra A Abu-Shmais, Matthew J Vukovich, Perry T Wasdin, Yukthi P Suresh, Toma M Marinov, Scott A Rush, Rebecca A Gillespie, Rajeshwer S Sankhala, Misook Choe, M Gordon Joyce and 3 more

Abstract read
In one paragraph

Article in mBio, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alexandra A Abu-ShmaisVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-5514-3277
Matthew J Vukovich *Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-7110-9623
Perry T Wasdin *Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Yukthi P SureshVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Toma M MarinovVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Scott A RushDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.
Rebecca A GillespieVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Rajeshwer S SankhalaEmerging Infectious Disease Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Misook ChoeEmerging Infectious Disease Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
M Gordon JoyceEmerging Infectious Disease Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.ORCID 0000-0002-6808-7232
Masaru KanekiyoVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, USA.ORCID 0000-0003-3991-542X
Ivelin S GeorgievVanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-6312-7696

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Influenza Vaccine Research and DevelopmentZIAAI005003 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI KANEKIYO, MASARU · 2009 to 2025
$89.8M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Vanderbilt Biomedical Informatics Training ProgramT15LM007450 · NLM · VANDERBILT UNIVERSITY · PI Jessica S. Ancker, Bradley A. Malin · 2002 to 2026
$19.7M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
VANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7M
Chemical Biology of Infectious Diseases (CBID) Training ProgramT32AI112541 · NIAID · VANDERBILT UNIVERSITY · PI Eric P Skaar · 2015 to 2026
$4.0M
High-throughput mapping of antigen specificity to B-cell-receptor sequence for characterizing antibody responses in HIV-vaccinated and infected individualsR01AI152693 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GEORGIEV, IVELIN · 2020 to 2023
$3.4M
Technologies for High-Throughput Mapping of Antigen Specificity to B-Cell-Receptor SequenceR01AI175245 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ivelin Georgiev · 2023 to 2026
$3.4M
G. Harold and Leila Y. Mathers Foundation (Mathers Foundation) MF-2107-01851HHS | National Institutes of Health (NIH) 5T32AI112541-07HHS | National Institutes of Health (NIH) ZIAAI005003HHS | NIH | National Institute of Environmental Health Sciences (NIEHS) T15LM007450-19Intramural NIH HHS ZIA AI005003NCATS NIH HHS UL1 TR002243NCI NIH HHS P30 CA068485NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIAID NIH HHS R01 AI152693NIAID NIH HHS R01 AI175245NIAID NIH HHS T32 AI112541NIDDK NIH HHS P30 DK058404NLM NIH HHS T15 LM007450Vanderbilt Institute for Clinical and Translational Research (VICTR) VR54735Welch Foundation (The Welch Foundation) F-0003-19620604
6 · The paper itself

Abstract

Throughout life, humans experience repeated exposure to viral antigens through infection and vaccination, resulting in the generation of diverse, antigen-specific antibody repertoires. A paramount feature of antibodies that enables their critical contributions in counteracting recurrent and novel pathogens, and consequently fostering their utility as valuable targets for therapeutic and vaccine development, is the exquisite specificity displayed against their target antigens. Yet, there is still limited understanding of the determinants of antibody-antigen specificity, particularly as a function of antibody sequence. In recent years, experimental characterization of antibody repertoires has led to novel insights into fundamental properties of antibody sequences but has been largely decoupled from at-scale antigen specificity analysis. Here, using the LIBRA-seq technology, we generated a large data set mapping antibody sequence to antigen specificity for thousands of B cells, by screening the repertoires of a set of healthy individuals against 20 viral antigens representing diverse pathogens of biomedical significance. Analysis uncovered virus-specific patterns in variable gene usage, gene pairing, somatic hypermutation, as well as the presence of convergent antiviral signatures across multiple individuals, including the presence of public antibody clonotypes. Notably, our results showed that, for B-cell receptors originating from different individuals but leveraging an identical combination of heavy and light chain variable genes, there is a specific CDRH3 identity threshold above which B cells appear to exclusively share the same antigen specificity. This finding provides a quantifiable measure of the relationship between antibody sequence and antigen specificity and further defines experimentally grounded criteria for defining public antibody clonality.IMPORTANCEThe B-cell compartment of the humoral immune system plays a critical role in the generation of antibodies upon new and repeated pathogen exposure. This study provides an unprecedented level of detail on the molecular characteristics of antibody repertoires that are specific to each of the different target pathogens studied here and provides empirical evidence in support of a 70% CDRH3 amino acid identity threshold in pairs of B cells encoded by identical IGHV:IGL(K)V genes, as a means of defining public clonality and therefore predicting B-cell antigen specificity in different individuals. This is of exceptional importance when leveraging public clonality as a method to annotate B-cell receptor data otherwise lacking antigen specificity information. Understanding the fundamental rules of antibody-antigen interactions can lead to transformative new approaches for the development of antibody therapeutics and vaccines against current and emerging viruses.

Indexed as

Antibodies, ViralAntigens, ViralB-LymphocytesAntibody SpecificityHumansAntibodies, ViralAntigens, Viralantibody repertoireantigen specificityB-cell repertoireB-cell responsespublic clonotypevirus

Identifiers

PMID39264172
PMCPMC11481873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.